Leap Therapeutics Files 8-K on Security Holder Vote
Ticker: CYPH · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Leap Therapeutics is having a shareholder vote, details to follow.
AI Summary
On July 2, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not specify the exact nature of the vote or any associated resolutions, but it indicates a formal process involving shareholder decisions is underway.
Why It Matters
This filing signals that Leap Therapeutics is engaging its shareholders in a formal decision-making process, which could impact the company's future direction or governance.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Leap Therapeutics, Inc. (company) — Registrant
- July 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37990 (identifier) — Commission File Number
- 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141 (address) — Principal executive offices
FAQ
What specific matters are being submitted for a vote of Leap Therapeutics' security holders?
The 8-K filing does not specify the exact matters to be voted on, only that matters are being submitted for a vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 2, 2024.
What is the principal executive office address for Leap Therapeutics?
The principal executive offices are located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.
In which state is Leap Therapeutics incorporated?
Leap Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Leap Therapeutics?
The Commission File Number for Leap Therapeutics is 001-37990.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-07-08 16:48:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate
Filing Documents
- tm2418993d1_8k.htm (8-K) — 32KB
- 0001104659-24-078325.txt ( ) — 201KB
- lptx-20240702.xsd (EX-101.SCH) — 3KB
- lptx-20240702_lab.xml (EX-101.LAB) — 33KB
- lptx-20240702_pre.xml (EX-101.PRE) — 22KB
- tm2418993d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. (a)Leap Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on July 2, 2024. (b)The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below. (1) The following director nominees were elected to serve as Class I directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes James Cavanaugh 16,740,789 1,392,072 7,871,104 Douglas E. Onsi 17,084,768 1,048,093 7,871,104 Christian Richard 17,809,064 323,797 7,871,104 Richard Schilsky 16,813,357 1,319,504 7,871,104 (2) The Company's stockholders approved, on an advisory basis, the executive compensation of the Company's named executive officers. Votes For Votes Against Votes Abstaining Broker Non-Votes 16,820,682 1,272,059 40,120 7,871,104 (3) The Amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved. Votes For Votes Against Votes Abstaining Broker Non-Votes 16,572,103 1,480,150 80,608 7,871,104 (4) The appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Votes For Votes Against Votes Abstaining 25,894,496 71,613 37,856
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: July 8, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President